Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29073835 | 0.87 | KMT2A (0.43) | KMT2AMAPTSMN1; SMN2TSHRTDP1 | |
| SCHEMBL28173189 | 0.82 | KMT2A (0.46) | LMNAKMT2AMAPTSMN1; SMN2TSHR | |
| SCHEMBL11501114 | 0.82 | CES2 (0.43) | LMNAF2MAPTTSHRKDM4E | |
| SCHEMBL27956762 | 0.79 | LOXL2 (0.44) | MAPTTSHRKDM4EHPGDRAB9A | |
| SCHEMBL1964113 | 0.78 | — | — | |
| SCHEMBL27472333 | 0.77 | KMT2A (0.50) | LMNAF2KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL28787723 | 0.77 | ALDH1A1 (0.33) | KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL27580003 | 0.76 | KDM4E (0.49) | LMNAKMT2AMAPTSMN1; SMN2TDP1 | |
| SCHEMBL20495492 | 0.76 | — | — | |
| SCHEMBL27831921 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3463338-A1 | ANTIMICROBIAL AGENTS AND THE METHOD OF SYNTHESIZING THE ANTIMICROBIAL AGENTS | Arkansas State University-Jonesboro (US) | 2019-04-10 | — | — | EP | claimed |
| WO-2017205814-A1 | ANTIMICROBIAL AGENTS AND THE METHOD OF SYNTHESIZING THE ANTIMICROBIAL AGENTS | ARKANSAS STATE UNIVERSITY-JONESBORO (US) | 2017-11-30 | — | — | WO | claimed |
| CN-114040937-B | Metal-organic framework material containing pyrazolyl benzoate ligand and preparation method thereof | 埃克森美孚科技工程公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-114040937-B | Metal-organic framework material containing pyrazolyl benzoate ligand and preparation method thereof | 埃克森美孚科技工程公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-219713911-U | Production is with pyrazolyl benzoic acid equipment | 天津大地康和医药技术有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-219713911-U | Production is with pyrazolyl benzoic acid equipment | 天津大地康和医药技术有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-219713911-U | Production is with pyrazolyl benzoic acid equipment | 天津大地康和医药技术有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-112209878-B | Cannabinoid receptor light-operated ligand and preparation method and application thereof | 上海科技大学 | 2022-07-05 | — | — | CN | disclosed |
| CN-114040937-A | Metal-organic framework materials comprising pyrazolyl benzoate ligands and methods of making the same | 埃克森美孚研究工程公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-114040937-A | Metal-organic framework materials comprising pyrazolyl benzoate ligands and methods of making the same | 埃克森美孚研究工程公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-3787621-A1 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | Enanta Pharmaceuticals, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-101253155-B | 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1 | HOFFMANN LA ROCHE | 2011-11-09 | — | — | CN | disclosed |
| CN-102089297-A | Novel 1,2,4 oxadiazole compounds and methods of use thereof | ABBOTT LAB | 2011-06-08 | — | — | CN | disclosed |
| US-7622492-B2 | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2009-11-24 | — | — | US | disclosed |
| CN-101253155-A | 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1 | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | CN | disclosed |
| EP-1924563-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007025892-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | BANNER BRUCE L | 2007-03-01 | — | — | US | disclosed |
| CN-1159180-A | Benzoyl derivatives and synthesis thereof | MONSANTO CO (US) | 1997-09-10 | — | — | CN | disclosed |
| CN-1156441-A | Benzoyl Derivatives and Their Synthesis | MONSANTO CO (US) | 1997-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | HSD17B1, HSD17B2, HSD3B2 | LMNA 3237/4885F2 3175/4885KMT2A 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.